Navigation Links
Barr Will Host Calendar 2007 Third Quarter Earnings Conference Call on November 8, 2007
Date:10/5/2007

WOODCLIFF LAKE, N.J., Oct. 5 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that the Company will host a Conference Call at 8:30 AM Eastern time on Thursday, November 8th to discuss earnings results for the third quarter of calendar 2007, ended September 30, 2007. The number to call from within the United States is: (866) 254-5941 and (651) 224-7558 Internationally. A replay of the conference call will be available from 12 Noon Eastern time on November 8th through 11:59 PM Eastern time November 15th, and can be accessed by dialing (800) 475-6701 in the United States or (320) 365-3844 Internationally and using the access code 889111.

The Conference Call will also be Webcast live on the Internet. Investors and other interested parties may access the live webcast through the Investors section, under Calendar of Events, on Barr's website at http://www.barrlabs.com.

Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 115 generic and 25 proprietary products in the U.S. and more than 1,200 products globally outside of the U.S.

Forward
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. AIDS awareness calendar in Tamilnadu, India.
2. Third artificial heart patient introduced
3. Extra hormone found to cut appetite by a third
4. Third generation Small pox vaccine from Cell-culture
5. Surgery Offers Better Treatment For Third Degree Piles
6. One Third Of All Cancers Preventable!
7. Britain Announces Third Transfusion Related Mad Cow Case
8. Kleins Third Way Has Tough Opposition
9. Ignorance about AIDS rampart in Third of College Students: Chinese survey
10. Wake-up Call: Two-thirds of Briton Spend Many Sleeping Moments Awake!
11. Jalgaon: Third Phase Of Culling Operations Begin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...Newswire/ -- The Children,s,Hospital of Philadelph...,gift that will enable the opening of a new pediat...gift, made possible by Athena and Nicholas,Karabot... the history of,Children,s Hospital and will give ...munities convenient access to world-class pediatri...
(Date:7/23/2008)... -- The American Heart,Association announces the c...t Award, the association,s highest honor for healt...ed in 2000, to recognize and honor the career,achi...s who have documented,the considerable progress ma...This career achievement award was created in memor...
(Date:7/23/2008)...mes may be tough, but,Hollywood,s young stars like...azzling new smile to boost confidence. Cosmetic de...clients beam in on success, citing his,experience ...fidence they,need for stardom. In agreement is Lan...smile designed by Dr. Kosdon., MTV,s Rock The Cra...
(Date:7/23/2008)...Newswire/ -- The Alameda County,Place Matters Team...akland,Marriott to address the social conditions t...om low-income and communities of color. Over 100,r...ll attend. Place Matters,is a national initiative ...dies, Health Policy Institute and is funded by the...
Breaking Medicine News(10 mins):Health News:$15 Million Donation From The Karabots Foundation Enables The Children's Hospital of Philadelphia to Open a New Pediatric Care Facility in Norristown, Pennsylvania 2Health News:$15 Million Donation From The Karabots Foundation Enables The Children's Hospital of Philadelphia to Open a New Pediatric Care Facility in Norristown, Pennsylvania 3Health News:Rock The Cradle's Bad Boy Landon Brown Owes His Irresistible New Smile to Dr. Michael Kosdon 2Health News:Alameda County Hosts National Initiative to Reduce Health Disparities 2
...t for esophageal reflux disease developed by a Wak...yngologist has been licensed to Bayer HealthCare’s...detects the presence of human pepsin 3b in a patie...man, M.D., then professor of otolaryngology at Wak...
...ld and running nose in children does not merit the...ised. In effect, antibiotics should be administere...tics are known to cause potential side effects. A...pretext, has led to the rise of germs, nicknamed a...
... Safety Authority Medsafe has approved the use of ...eral health professionals are calling for its use ... is said to offer immunity against four strains of...common sexually transmitted infection. Although HP...
...asingly unchecked spread of the HIV/AIDS epidemic ... coming years according to a report on the Macroec...udy was conducted by the National Council of Appli...ed by the the United Nations Development Programme...
Other Medicine News:Health News:Test for Esophageal Reflux Licensed to Bayer by University 2Health News:HIV/AIDS Epidemic to Cause Adverse Effects to Indian Economy 2
(Date:7/22/2008)... July 22 /- Following a,tho...ard of Progen,Pharmaceuticals Limited (ASX: PGL; N...ued the PI-88 phase 3 study in liver cancer. Proge... existing portfolio of compounds and,the company w...and,opportunities through Merger & Acquisition act...
(Date:7/22/2008)...Therapeutics Development Initiative bring MJFF,s,c...deadline January 20,2009, NEW YORK, July 22 /PRN...peed delivery of transformative treatments and a c...undation for Parkinson,s Research has awarded,$2.7... teams. The awards,were granted under MJFF,s Thera...
(Date:7/22/2008)...Study Confirms Tyrima Exhibits Excellent Drug-Like... Results Support Initiation of Phase II Clinical T...RNewswire/ -- CeNeRx BioPharma,Inc., a clinical s...tive,treatments for diseases of the central nervou...d candidate Tyrima(TM) into Phase II trials for th...
(Date:7/22/2008)... Calif., July 22 /- Hyperion,Therapeu...atient enrollment,in its Phase 1/2 clinical trial ...cavenging effects of HPN-100 (formally called GT4P...tients with urea cycle disorders,(UCD). The compan... quarter,of this year., (Logo: http://www.newsco...
Breaking Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Marital Status Doesnt Affect Lung Cancer Survival 1121 1Marital Status Doesnt Affect Lung Cancer Survival 1121 2Marital Status Doesnt Affect Lung Cancer Survival 1121 3Grubb 26 Ellis Healthcare REIT Acquires Park Place Office Park in Dayton Ohio 8925 1Grubb 26 Ellis Healthcare REIT Acquires Park Place Office Park in Dayton Ohio 8925 2Grubb 26 Ellis Healthcare REIT Acquires Park Place Office Park in Dayton Ohio 8925 3Pennsylvania Invests 2413 4 Million to Kick Off Butler Memorial Hospital Expansion 8923 1Pennsylvania Invests 2413 4 Million to Kick Off Butler Memorial Hospital Expansion 8923 2Eclipsys to Present at 10th Annual Needham Growth Stock Conference 8920 1Eclipsys to Present at 10th Annual Needham Growth Stock Conference 8920 2Eclipsys to Present at 10th Annual Needham Growth Stock Conference 8920 3
...nship Between Ability to Function and Treatment of...DIANAPOLIS, May 21, 2007 /PRNewswire-FirstCall/ --...ty disorder (GAD),treated with Cymbalta(R) (duloxe...everyday activities at home, work and in social,si...s in global,functioning were the result of improve...
...TER, MN, May 21, 2007-- Serotonin is a,neurotransm...yo,Clinic researchers set out to determine the rol... The study involved 48 females --,including indivi...duals with both IBS and dyspepsia, and healthy vol...nd intestines of each,patient and serotonin levels...
Other Medicine Technology:Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 2Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 3Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 4Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 5Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 6
Basic-level interpretive resting ECG
XALATAN is a prescription medicine used to lower eye pressure, also called intraocular pressure, or IOP, in patients with ocular hypertension (abnormally high IOP) or open-angle glaucoma.
The ECG-9010 meets IEC60601-2-51 new international standard for digital electrocardiographs specifying accuracy and digital filter performance. ECG data can be reviewed and managed on a Windows PC wi
The UltraVac V1 allows for unprecedented chamber stability and high vacuum levels with venturi systems. Vacuum and flow are proportionately linked on a venturi pump and cannot be independently adjust
Medicine Products: